Loading
A phase 2 trial of TAK-007 in non-Hodgkin lymphoma, run by Takeda, active and no longer recruiting.
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) is a phase 2 interventional study registered as NCT05020015 by Takeda, with 27 participants enrolled, started 2021-11-12 and due to reach its primary completion in 2024-06-16. Interventions recorded: TAK-007 and Chemotherapy Agents. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
27 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2025-08-12), not from a publication
Sourcerange 1.7 to 20.3; Figures from the ClinicalTrials.gov results section (first posted 2025-08-12), not from a publication · Median was not estimable due to insufficient number of participants with events. · range 0.9 to 11.2 · Median was not estimable due to insufficient number of participants with events.
Sourcerange 0.85 to 1.02; Figures from the ClinicalTrials.gov results section (first posted 2025-08-12), not from a publication · range 0.95 to 9.00 · range 0.03 to 5.55 · range 2.83 to 8.77
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs)primary | Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells | 3 | 3 participants | - | - | link |
| Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 6 | 6 participants | ||||
| Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 10 | 10 participants | ||||
| Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 7 | 7 participants | ||||
| Overall Survival (OS) | Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells | 3 | 8.9 months | - | - | link |
| Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 6 | Median was not estimable due to insufficient number of participants with events. | ||||
| Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 10 | 8.4 months | ||||
| Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 7 | Median was not estimable due to insufficient number of participants with events. | ||||
| Progression-free Survival (PFS) Per Investigator | Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells | 3 | 0.95 months | - | - | link |
| Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 6 | 2.23 months | ||||
| Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 10 | 2 months | ||||
| Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 7 | 5.62 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/